Bruce Booth Sells 16,740 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Free Report) Director Bruce Booth sold 16,740 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total value of $593,433.00. Following the transaction, the director now directly owns 803,792 shares in the company, valued at $28,494,426.40. The sale was disclosed in a filing with the SEC, which is available through this link.

Kymera Therapeutics Stock Down 4.5 %

Shares of NASDAQ KYMR traded down $1.58 during midday trading on Friday, reaching $33.29. 408,445 shares of the stock were exchanged, compared to its average volume of 659,301. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -13.26 and a beta of 2.25. The firm has a 50-day simple moving average of $35.05 and a two-hundred day simple moving average of $33.38. Kymera Therapeutics, Inc. has a twelve month low of $9.60 and a twelve month high of $45.31.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.04. The company had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The firm’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.70) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -2.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on KYMR. HC Wainwright reiterated a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 3rd. JPMorgan Chase & Co. boosted their price target on Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Truist Financial lifted their target price on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Stifel Nicolaus increased their price target on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Finally, Oppenheimer decreased their price objective on shares of Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $42.70.

View Our Latest Research Report on KYMR

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently modified their holdings of the business. Campbell & CO Investment Adviser LLC purchased a new position in Kymera Therapeutics during the fourth quarter worth approximately $792,000. BVF Inc. IL raised its stake in shares of Kymera Therapeutics by 8.9% during the 4th quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock worth $131,419,000 after buying an additional 422,797 shares during the period. Seven Eight Capital LP purchased a new position in shares of Kymera Therapeutics during the 4th quarter valued at approximately $571,000. Dark Forest Capital Management LP grew its stake in Kymera Therapeutics by 89.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 36,698 shares of the company’s stock valued at $510,000 after acquiring an additional 17,280 shares during the period. Finally, FMR LLC increased its holdings in Kymera Therapeutics by 3.9% in the 3rd quarter. FMR LLC now owns 870,547 shares of the company’s stock worth $12,101,000 after acquiring an additional 32,335 shares in the last quarter.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Featured Articles

Insider Buying and Selling by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.